Alvotech Expands US Manufacturing with LOTTE Biologics Partnership
Event summary
- Alvotech partners with LOTTE Biologics for US-based manufacturing of multiple biosimilar products at LOTTE’s Syracuse facility.
- The Syracuse site has 40,000 liters of bioreactor capacity and recently passed an FDA inspection with zero observations.
- The long-term agreement aims to increase Alvotech’s global manufacturing capacity and support growing demand for its biosimilar portfolio.
- Commercial supply is contingent on successful technology transfer, manufacturing qualification, and regulatory approvals.
The big picture
This partnership aligns with the broader trend of biotech companies outsourcing manufacturing to specialized CDMOs to enhance flexibility and scalability. Alvotech’s move to expand its US-based manufacturing footprint comes as biosimilars gain traction globally, driven by cost pressures and patent expirations of blockbuster biologics. The collaboration with LOTTE Biologics positions Alvotech to better compete in the rapidly growing biosimilar market, where supply chain efficiency is critical.
What we're watching
- Capacity Utilization
- How quickly Alvotech will ramp up production at LOTTE Biologics’ Syracuse facility to meet global demand.
- Regulatory Approvals
- The pace at which the partnership secures necessary regulatory approvals for commercial supply.
- Pipeline Expansion
- Whether the additional manufacturing capacity will support Alvotech’s long-term pipeline growth.
Related topics
